When less may not be best--the challenge of individualising antiviral therapy for chronic hepatitis C infection

J Gastroenterol Hepatol. 2009 Mar;24(3):330-2. doi: 10.1111/j.1440-1746.2009.05788.x.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / adverse effects
  • Asian People
  • Drug Therapy, Combination
  • Genotype
  • Hepacivirus / genetics*
  • Hepatitis C, Chronic / diagnosis
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / ethnology
  • Humans
  • Injections, Subcutaneous
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage*
  • Interferon-alpha / adverse effects
  • Polyethylene Glycols
  • RNA, Viral / blood
  • Recombinant Proteins
  • Ribavirin / administration & dosage*
  • Ribavirin / adverse effects
  • Time Factors
  • Treatment Outcome
  • Viral Load
  • White People

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • RNA, Viral
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2b